CAMS Therapy for Suicidal Thoughts
What You Need to Know Before You Apply
What is the purpose of this trial?
This study, titled "Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study," aims to better understand the brain mechanisms underlying suicidal thoughts and behaviors in adolescents and young adults (ages 14-24). Suicide is a leading cause of death in this population, and current clinical approaches often fail to accurately predict or prevent suicidal behavior. This study seeks to identify objective neurobiological markers associated with suicide risk and treatment response.
Participants will be divided into three groups: (1) high-risk individuals recently hospitalized following a suicide attempt, (2) medium-risk individuals with chronic suicidal ideation but no attempts, and (3) low-risk healthy controls. All participants will undergo advanced neuroimaging, including magnetoencephalography (MEG) and magnetic resonance imaging (MRI), along with comprehensive psychiatric assessments.
The study focuses on brain regions and networks implicated in suicidality, including the anterior cingulate cortex and salience network, as well as neurochemical markers such as glutamate. It also examines electrophysiological activity and functional connectivity patterns associated with suicidal thoughts and behaviors.
High-risk participants will receive an evidence-based psychotherapy called the Collaborative Assessment and Management of Suicidality (CAMS). This therapeutic approach emphasizes collaboration between patient and clinician to identify and address the underlying drivers of suicidal thoughts, with a focus on increasing hope and reducing psychological distress. Neuroimaging and clinical assessments will be repeated after completion of CAMS to evaluate treatment-related changes.
The study's primary goals are to:
* Identify neural and electrophysiological correlates of suicide risk.
* Distinguish biological differences between individuals with suicidal ideation and those who have attempted suicide.
* Determine how CAMS therapy affects brain function and neurochemistry.
By integrating clinical and neurobiological data, this research aims to improve understanding of suicidality, enhance risk prediction, and inform more effective, personalized interventions for at-risk youth.
Who Is on the Research Team?
Tatiana Falcone, M.D.
Principal Investigator
The Cleveland Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline neuroimaging and psychiatric assessments
Treatment
High-risk participants receive CAMS therapy, typically involving weekly sessions
Post-Treatment Assessment
Repeat neuroimaging and clinical assessments to evaluate treatment-related changes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Collaborative Assessment and Management of Suicidality (CAMS)
How Is the Trial Designed?
3
Treatment groups
Active Control
patients discharged within 1 week from the hospital for a SA and with a history of 2 previous SAs
patients with 1 year history of SI with no attempts
age-matched controls with no prior history of SI or behavior, not taking any psychotropic medication and no family history of suicide
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor
MQ Mental Health Research
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.